Study of liposomal irinotecan for advanced pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study looks at how well a treatment called liposomal irinotecan works for people with advanced pancreatic cancer that has spread. You may qualify if you have already tried a chemotherapy drug called gemcitabine and it stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have locally advanced or metastatic pancreatic cancer (confirmed by biopsy).
- For the experimental group: you have already received at least one round of the study drug combination (liposomal irinotecan + 5-FU/LV).
- You have had pancreatic cancer that got worse while on gemcitabine or a treatment that included gemcitabine.
- You agree to take part in the study and sign a consent form.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy for people with advanced pancreatic cancer that cannot be removed by surgery or has spread. It may be an option if you have already tried at least one previous treatment or if you have not had any treatment yet, depending on the study group.
This trial tests a new liposomal form of irinotecan in combination with other drugs as a second or later treatment for people with advanced pancreatic cancer that continued to grow after prior irinotecan therapy. It aims to see if this new combination can help shrink tumors or slow the cancer's growth.
This study looks at how well a specific type of chemotherapy called irinotecan hydrochloride liposome works in people with pancreatic cancer. Researchers want to understand its effects in real-world settings, which may help doctors choose the best treatment for patients.
This study tests a new form of chemotherapy called liposomal irinotecan (Nal-IRI) for people with advanced colorectal cancer or other solid tumors. The goal is to see how well it works and how safe it is in real-world settings.
This trial tests a combination of chemotherapy (Nal-IRI, 5-FU, leucovorin), an immunotherapy drug (PD-L1 inhibitor), and a targeted anti-angiogenic pill, with or without radiation (SBRT), as a second-line treatment for people with metastatic pancreatic cancer that has progressed after first-line therapy.
This trial tests a combination of two chemotherapy drugs (irinotecan liposome and capecitabine) for people with pancreatic cancer that has spread or cannot be removed by surgery and has gotten worse after initial treatment. The goal is to see if this combination can help slow the disease.
Hear when a new Advanced Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.